SLC6A7 and acute myeloid leukemia: Given that somatic mutations within the i-prot have been associated with an increased risk for developing AML and that iCP subunits are robustly overexpressed in primary AML cells, the i-prot is an attractive target for further drug development.43, 44, 45 Whether or not i-prot inhibition is more efficacious than c-prot inhibition (and whether any efficacy holds for LSCs), however, remains to be seen.